Akari Therapeutics shares rise 10.21% premarket after filing patent for AKTX-102 targeting CEACAM5, expanding ADC pipeline.

Akari Therapeutics surged 10.21% in premarket trading following the announcement of a U.S. provisional patent filing for AKTX-102, a CEACAM5-targeted ADC. The company expanded its pipeline by leveraging its proprietary PH1 spliceosome payload and novel antibody design to address a high-value but historically challenging oncology target expressed in up to 90% of gastrointestinal cancers. The filing strengthens Akari’s intellectual property estate, builds on its lead program AKTX-101’s regulatory milestones, and highlights differentiation in ADC innovation. The news underscores progress in developing next-generation therapies with potential for best-in-class efficacy, aligning with investor optimism around the company’s expanding pipeline and proprietary technology.